Ulcerative colitis has long been framed as a disease of overactive immunity, a condition in which the immune system attacks ...

Leading biotech stock Abivax (ABVX) jumped Monday on compelling test results for its experimental ulcerative colitis treatment. The company tested its drug, obefazimod, in patients with ulcerative ...

In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than ...

Targeting the gut microbiome with fecal microbiota transplantation (FMT) may help cancer patients with immunotherapy-related ...

Tvardi Therapeutics, Inc. announced the publication of preclinical data evaluating Tvardi?s STAT3 inhibitor in the International Journal of Molecular Sciences. The publication provides additional ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

A new drug for treating a type of inflammatory bowel disease (IBD) has been given the go-ahead by the Food and Drug Administration. On Friday, the FDA approved Pfizer’s etrasimod, branded as Velsipity ...

Ottawa, May 09, 2024 (GLOBE NEWSWIRE) -- The global ulcerative colitis treatment market size was valued at USD 10.16 billion in 2023 and is predicted to hit around USD 13.81 billion by 2032, a study ...

New research reveals a gap between support for earlier advanced therapy and real-world prescribing in Japan, with many ...

Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown role for B cells, which ...

Abivax (NASDAQ:ABVX) shares fell sharply on Tuesday after investors focused on reports of rare malignancy cases in a late-stage clinical trial, overshadowing better-than-expected efficacy results for ...